Veregen (sinecatechins ointment)

Veregen (sinecatechins ointment) is filed as Topical Antiviral. The sections below restate public label fields stored for this profile.

Class
Topical Antiviral
Generic name
sinecatechins ointment
Route
TOPICAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Ointment, 15% w/w. Each gram of Veregen Ointment, 15% contains 150 mg of sinecatechins in a brown ointment base. Ointment, 15% (3)
Manufacturer
ANI Pharmaceuticals, Inc.

Approved uses

1 INDICATIONS AND USAGE Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older (1.1) . Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses (1.2) . 1.1 Indication Veregen is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. 1.2 Limitations of Use The safety and effectiveness of Veregen have not been established for treatment beyond 16-weeks or for multiple treatment courses. The safety and effectiveness of Veregen in immunosuppressed patients have not been established.

How it works

12.1 Mechanism of Action The mode of action of Veregen involved in the clearance of genital and perianal warts is unknown. In vitro, sinecatechins had anti-oxidative activity; the clinical significance of this finding is unknown.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Veregen ® has not been evaluated for the treatment of urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used for the treatment of these conditions. Use of Veregen ® on open wounds should be avoided. Patients should be advised to avoid exposure of the genital and perianal area to sun/UV-light as Veregen ® has not been tested under these circumstances. • Veregen ® should not be used to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease (5) . • Use of Veregen ® on open wounds should be avoided (5) . • Avoid exposure of Veregen ® treated areas to sun/UV-light as Veregen ® has not been tested under these circumstances (5) .

Contraindications

4 CONTRAINDICATIONS None None (4)

Common side effects

Nflammation were reported in two subjects (0.5%); Subjects (2.4%)

Adverse reactions

6 ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In Phase 3 clinical trials, a total of 397 subjects received Veregen three times per day topical application for the treatment of external genital and perianal warts for up to 16 weeks. Serious local adverse events of pain and inflammation were reported in two subjects (0.5%), both women. In clinical trials, the incidence of patients with local adverse events leading to discontinuation or dose interruption (reduction) was 5% (19/397). These included the following events: application site reactions (local pain, erythema, vesicles, skin erosion/ulceration), phimosis, inguinal lymphadenitis, urethral meatal stenosis, dysuria, genital herpes simplex, vulvitis, hypersensitivity, pruritus, pyodermitis, skin ulcer, erosions in the urethral meatus, and superinfection of warts and ulcers. Local and regional reactions (including adenopathy) occurring at >1% in the treated groups are presented in Table 1. Table 1: Local and Regional Adverse Reactions During Treatment (% Subjects) Veregen ® (N = 397) Vehicle (N = 207) Erythema 70 32 Pruritus 69 45 Burning 67 31 Pain/discomfort 56 14 Erosion/Ulceration 49 10 Edema 45 11 Induration 35 11 Rash vesicular 20 6 Regional Lymphadenitis 3 1 Desquamation 5 <1 Discharge 3 <1 Bleeding 2 <1 Reaction 2 0 Scar 1 0 Irritation 1 0 Rash 1 0 A total of 266/397 (67%) of subjects in the Veregen group had either a moderate or a severe reaction that was considered probably related to the drug, of which 120 (30%) subjects had a severe reaction. Severe reactions occurred in 37% (71/192) of women and in 24% (49/205) of men. The percentage of subjects with at least one severe, related adverse event was 26% (86/328) for subjects with genital warts only, 42% (19/45) in subjects with both genital and perianal warts and 48% (11/23) of subjects with perianal warts only. Phimosis occurred in 3% of uncircumcised male subjects (5/174) treated with Veregen and in 1% (1/99) in vehicle. The maximum mean severity of erythema, erosion, edema, and induration was observed by week 2 of treatment. Less common local adverse events included urethritis, perianal infection, pigmentation changes, dryness, eczema, hyperesthesia, necrosis, papules, and discoloration. Other less common adverse events included cervical dysplasia, pelvic pain, cutaneous facial rash, and staphylococcemia. In a dermal sensitization study of Veregen in healthy volunteers, hypersensitivity (type IV) was observed in 5 out of 209 subjects (2.4%) under occlusive conditions. Most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and rash vesicular (6) . To report SUSPECTED ADVERSE REACTIONS, ANI Pharmaceuticals, Inc. at 1-800-308-6755 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Dosage and administration

2 DOSAGE AND ADMINISTRATION • Veregen is to be applied three times per day to all external genital and perianal warts (2.1) . • Apply about an 0.5 cm strand of ointment to each wart using the finger(s), dabbing it on to ensure complete coverage and leaving a thin layer of the ointment on the warts (2.1) . • Veregen is not for ophthalmic, oral, intravaginal, or intra-anal use (2.1) . 2.1 General Dosing Information Veregen is to be applied three times per day to all external genital and perianal warts. Apply about an 0.5 cm strand of the Veregen to each wart using the finger(s), dabbing it on to ensure complete coverage and leaving a thin layer of the ointment on the warts. Patients should wash their hands before and after application of Veregen. It is not necessary to wash off the ointment from the treated area prior to the next application. Veregen ® is not for ophthalmic, oral, intravaginal, or intra-anal use. 2.2 Treatment Period Treatment with Veregen should be continued until complete clearance of all warts, however no longer than 16 weeks. Local skin reactions (e.g. erythema) at the treatment site are frequent. Nevertheless, treatment should be continued when the severity of the local skin reaction is acceptable.

Patient counseling

17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) Patients using Veregen should receive the following information and instructions: • This medication is only to be used as directed by a physician. It is for external use only. Eye contact should be avoided as well as application into the vagina or anus. • It is not necessary to wash off Veregen prior to the next application. When the treatment area is washed or a bath is taken, the ointment should be applied afterwards. • It is common for patients to experience local skin reactions such as erythema, erosion, edema, itching, and burning at the site of application. Severe skin reactions can occur and should be promptly reported to the healthcare provider. Should severe local skin reaction occur, the ointment should be removed by washing the treatment area with mild soap and water, and further doses withheld. • Sexual (genital, anal or oral) contact should be avoided while the ointment is on the skin, or the ointment should be washed off prior to these activities. Veregen may weaken condoms and vaginal diaphragms. Therefore, the use in combination with Veregen is not recommended. • Female patients using tampons should insert the tampon before applying the ointment. If the tampon is changed while the ointment is on the skin, accidental application of the ointment into the vagina must be avoided. • Veregen may stain clothing and bedding. • Veregen is not a cure and new warts might develop during or after a course of therapy. If new warts develop during the 16-week treatment period, these should also be treated with Veregen. • The effect of Veregen on the transmission of genital/perianal warts is unknown. • Patients should be advised to avoid exposure of the genital and perianal area to sun/UV light as Veregen has not been tested under these circumstances. • The treatment area should not be bandaged or otherwise covered or wrapped as to be occlusive. • Uncircumcised males treating warts under the foreskin should retract the foreskin and clean the area daily.

Common questions

What is Veregen approved to treat?

According to its FDA label, Veregen (sinecatechins ointment) is approved for: 1 INDICATIONS AND USAGE Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older (1.1) . Limitations of Use Safety and effectiveness of Veregen have not been established… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Veregen?

Veregen (sinecatechins ointment) belongs to the Topical Antiviral class of medications.

What form does Veregen come in?

The FDA label lists Veregen (sinecatechins ointment) as: 3 DOSAGE FORMS AND STRENGTHS Ointment, 15% w/w. Each gram of Veregen Ointment, 15% contains 150 mg of sinecatechins in a brown ointment base. Ointment, 15% (3); topical route. Available strengths and packaging vary by manufacturer.

Does Veregen have a Boxed Warning?

Our ingest of the FDA label for Veregen (sinecatechins ointment) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Veregen cost?

Public CMS NADAC pricing for Veregen (sinecatechins ointment) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Veregen currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Veregen (sinecatechins ointment) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Veregen approved by the FDA?

The FDA record lists the approval date for Veregen (sinecatechins ointment) as 2006-10-31.

Who makes Veregen?

The FDA label lists ANI Pharmaceuticals, Inc. as a labeler/manufacturer of Veregen (sinecatechins ointment). Multiple firms may market generics of the same molecule.

How should Veregen be stored?

The FDA label states: "Prior to dispensing to the patient, store refrigerated 2°C to 8°C (36°F to 46°F). After dispensing, store refrigerated or up to 25°C (77°F). Do not freeze. KEEP OUT OF THE REACH OF CHILDREN." Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…